Concomitant use of nesiritide and milrinone in decompensated congestive heart failure

American Journal of Health-System Pharmacy

Volumn 62, Issue 3, 2005, Pages 291-295

  Smull, David L ^a,b   Jorde, Ulrich P ^c,d  

^a FORSYTH MEDICAL CENTER   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CPMC

Author keywords

[No Author keywords available]

Indexed keywords

MILRINONE; NESIRITIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART AFTERLOAD; HEART PRELOAD; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME;

EID: 15044355235     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.3.291     Document Type: Article

References (15)

1. Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998; 4:37-44.
2. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002; 287:1531-40.
3. Shipley JB, Tolman D, Hastillo A et al. Milrinone: basic and clinical pharmacology and acute and chronic management. Am J Med Sci. 1996; 311:286-91.
4. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992; 86:1081-8.
5. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol. 2001; 38:923-31.
6. Deb B, Bradford K, Pearl RG. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med. 2000; 28:795-9.
7. Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996; 94:3184-9.
8. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000; 343:246-53.
9. Cigarroa RG, Lange RA, Williams RH et al. Underestimation of cardiac output by thermodilution in patients with tricuspid regurgitation. Am J Med. 1989; 86:417-20.
10. Lipkin DP, Poole-Wilson PA. Measurement of cardiac output during exercise by the thermodilution and direct Fick techniques in patients with chronic congestive heart failure. Am J Cardiol. 1985; 56:321-4.
11. Sandner P, Kornfeld M, Ruan X et al. Nitric oxide/cAMP interactions in the control of rat renal vascular resistance. Circ Res. 1999; 84:186-92.
12. Delpy E, Coste H, Gouville AC. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol. 1996; 119:471-8.
13. Kauffman RF, Schenck KW, Utterback BG et al. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther. 1987; 242:864-72.
14. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995; 75:725-48.
15. Jensen KT, Eiskjaer H, Carstens J et al. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci. 1999; 96:5-15.